New smart insulin tool could simplify mealtime for teens with diabetes
NCT ID NCT07212179
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new self-learning bolus calculator that simplifies meal announcements for adolescents and young adults with type 1 diabetes using automated insulin delivery. Two participants used the system first in a hotel and then at home to see if it was safe and feasible. The goal was to help manage blood sugar levels more easily without needing complex meal calculations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
2 people
The number who actually took part.
- Started
-
Mar 2026
- Finished
-
Apr 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
14 to 21 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Age ≥14.0 and ≤21 years old at time of consent 2. HbA1c ≤ 10%. 3. Clinical diagnosis, based on investigator assessment, of type 1 diabetes for at least one year 4. Having used an insulin pump within the last three months. 5. Currently using insulin for at least six months 6. Willingness to use insulin parameters such as carbohydrate ratio and correction factors consistently on their pump in order to dose insulin for meals or corrections 7. Willingness to switch to a commercially approved insulin (e.g. lispro or aspart or biosimilar approved products) within the study pump as directed by the study team. 8. Has one or more supportive caregivers or companions living with the participant who are knowledgeable about emergency procedures for treatment of severe hypoglycemia and able to contact emergency services and study staff. 9. Acceptable forms of contraception for participants of child-bearing potential include hormonal treatments including IUD, abstinence from heterosexual intercourse, vasectomy in partner, barrier methods (e.g. condom or diaphragm). 10. For females, not currently known to be pregnant or breastfeeding. A negative serum or urine pregnancy test will be required for all females of childbearing potential. Participants who become pregnant will be discontinued from the study. Also, participants who during the study develop and express the intention to become pregnant within the timespan of the study will be discontinued. 11. Willingness to use the study InsuLearn system (CGM, pump, and phone) during the study period. 12. Willingness not to start any new non-insulin glucose-lowering agent during the course of the trial. 13. Access to internet at home and ability to upload data during the study as needed. 14. Investigator has confidence that the participant can successfully operate all study devices and is capable of adhering to the protocol. 15. Participant is proficient in reading and writing English. Exclusion Criteria: 1. History of diabetic ketoacidosis (DKA) in the 12 months prior to enrollment 2. Severe hypoglycemia resulting in seizure or loss of consciousness in the 12 months prior to enrollment 3. Pregnancy or intent to become pregnant during the trial 4. Currently breastfeeding or planning to breastfeed 5. Currently being treated for a seizure disorder 6. Planned surgery during study duration 7. History of cardiac arrhythmia (except for benign premature atrial contractions and benign premature ventricular contractions which are permitted) 8. Treatment with any non-insulin glucose-lowering agent (including metformin, GLP-1 agonists, pramlintide, DPP-4 inhibitors, SGLT-2 inhibitors, biguanides, sulfonylureas and naturaceuticals) 9. A known medical condition that in the judgment of the investigator might interfere with the completion of the protocol. 10. Participation in another interventional trial at the time of enrollment. 11. Visual impairment/blindness that prevents proper interaction with study equipment 12. Participant who may have a falsely eligible HbA1c due to medical conditions or blood donations. 13. Participants in whom the G6 CGM may be inaccurate due to interference.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Type 1 diabetes are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Virginia Center for Diabetes Technology
Charlottesville, Virginia, 22903-2981, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can skin sensors replace finger pricks for diabetes care in kenya?
- Tiny horses, big lessons: can ponies help kids tame diabetes?
- Can a math model tune insulin pumps better than standard care?
- Can a group program stop eating disorders in type 1 diabetes?
- Can a Two-Punch immune therapy save insulin cells in newly diagnosed diabetes?
- Can a smart insulin pump tailored for pregnancy protect mothers and babies?